Compare · MEDS vs VCYT
MEDS vs VCYT
Side-by-side comparison of DataMeds AI Inc. (MEDS) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. MEDS focuses on Other Pharmaceuticals, while VCYT focuses on Medical Specialities.
- VCYT is the larger of the two at $1.94B, about 625.0x MEDS ($3.1M).
- Over the past year, MEDS is down 98.0% and VCYT is down 38.8% - VCYT leads by 59.2 points.
- VCYT has been more active in the news (12 items in the past 4 weeks vs 5 for MEDS).
- VCYT has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- DataMeds AI Inc.
- Veracyte Inc.
- Price
- -
- -
- Market cap
- $3.1M
- $1.94B
- 1M return
- -77.82%
- -44.40%
- 1Y return
- -98.02%
- -38.83%
- Industry
- Other Pharmaceuticals
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- News (4w)
- 5
- 12
- Recent ratings
- 1
- 25
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Veracyte Inc.
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest MEDS
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Latest VCYT
- Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.
- SEC Form 10-Q filed by Veracyte Inc.
- Veracyte downgraded by Leerink Partners with a new price target
- Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Veracyte Announces Third Quarter 2026 Financial Results
- Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
- SEC Form 4 filed by Veracyte Inc.
- Veracyte to Participate in Upcoming Investor Conferences
- Director Eastham Karin sold $742,573 worth of shares (14,850 units at $50.00) as part of a pre-agreed trading plan (SEC Form 4)